Efficacy and safety of larotrectinib in patients with TRK fusion lung cancer: An updated analysis.
Jessica Jiyeong Lin, D SW Shao-Weng Tan, Alexander E. Drilon, Victor Moreno et autres
1 citationJournal of Clinical Oncology
Natascha Neu
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
18Publications signalées
85Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Lung Cancer Treatments and MutationsCholangiocarcinoma and Gallbladder Cancer StudiesGlioma Diagnosis and TreatmentNeuroblastoma Research and TreatmentsPancreatic and Hepatic Oncology Research
Publications récentes
Efficacy and safety of larotrectinib in patients with non-primary central nervous system TRK fusion cancer: An updated analysis.
Alexander E. Drilon, Rui‐Hua Xu, David S. Hong, Cornelis M. van Tilburg et autres
0 citationsJournal of Clinical Oncology
Abstract A029: Larotrectinib long-term efficacy and safety in pediatric patients with TRK fusion non-primary CNS tumors: Analysis update
Leo Mascarenhas, Theodore W. Laetsch, Birgit Geoerger, Steven G. DuBois et autres
0 citationsCancer Research
Abstract P4-08-29: Efficacy and safety of larotrectinib in patients with TRK fusion breast cancer: an updated analysis
Cristiano Freitas de Souza, Ezra Y. Rosen, Antoine Italiano, Felipe Melo Cruz et autres
0 citationsClinical Cancer Research
Efficacy and safety of larotrectinib in patients with TRK fusion thyroid carcinoma: An updated analysis.
Marcia S. Brose, Maria E. Cabanillas, Mohammed Almubarak, Jessica R. Bauman et autres
0 citationsJournal of Clinical Oncology
Efficacy and safety of larotrectinib in patients with TRK fusion lung cancer: An updated analysis.
Daniel Shao-Weng Tan, Alexander Drilon, Víctor Moreno, Shivaani Kummar et autres
2 citationsJournal of Clinical Oncology
Larotrectinib resistance in TRK fusion cancers: Analysis of a tumor-agnostic, global clinical trial dataset.
Alexander Drilon, David S. Hong, Daniel Orbach, Daniel Shao-Weng Tan et autres
0 citationsJournal of Clinical Oncology
Efficacy and safety of larotrectinib in patients with non-primary central nervous system TRK fusion cancer: An updated analysis.
Rui‐Hua Xu, David S. Hong, Cornelis M. van Tilburg, Daniel Orbach et autres
1 citationJournal of Clinical Oncology
Long-term Efficacy and Safety of Larotrectinib in Pediatric Patients with Primary CNS and Non-Primary CNS TRK Fusion Tumors
Omar Chamdine, Leo Mascarenhas, François Doz, Birgit Geoerger et autres
0 citationsOncoDaily Medical Journal
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
Changsong Qi, Lin Shen, Thierry André, Hyun Cheol Chung et autres
23 citationsEuropean Journal of Cancer
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Leo Mascarenhas, Steven G. DuBois, Catherine M. Albert, Stefan Bielack et autres
0 citationsJournal of Clinical Oncology
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Leo Mascarenhas, Steven G. DuBois, Catherine M. Albert, Stefan Bielack et autres
0 citationsJournal of Clinical Oncology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.